Overview of SARS-CoV-2 Mutant Variants

Recombinant SARS-CoV-2 Proteins

The spread of the 2019 new Coronavirus (SARS-CoV-2) throughout the world has a strong impact on our daily life and the fight against COVID-19 is one of the most important tasks of the scientific world in these days.

​To support COVID-19 research, we produce ready-to-use recombinant SARS-CoV-2 proteins which can be used as antigen for analytic and immunodiagnostic purposes as well as for vaccine development.

Find recombinant SARS-CoV-2 Proteins in our Webshop

In our webshop you will find ready-to-use SARS-CoV-2 (COVID-19) proteins like SARS-COV-2 Spike S, SARS-CoV-2 Spike S1 RBD, Nucleocapsid (N) protein, Proteinase 3 CL-Mpro, M protein, Envelope (E) protein and other relevant proteins that are associated with Coronavirus infection like hACE2 protein. In addition, we offer a wide range of important SARS-CoV-2 Variants (Spike Mutant Proteins). All proteins can be ordered from stock and have very short delivery times.


“In our COVID-19 projects, we have had very good experience with the SARS-CoV-2 proteins produced by trenzyme: rapid and reliable production of the functional proteins from different cell lines continued to provide first-class support for our projects.”

Dr. Peter Rauch

CANDOR Bioscience GmbH, Wangen, Germany

Spike S1 (RBD)

Search for various variants of the SARS-CoV-2 (COVID-19) Spike S1 (RBD) protein in our webshop

S trimer

Find different variants of the Spike protein, stabilized trimer, of SARS-CoV-2 (COVID-19) in our webshop

Spike Mutant Proteins

Variety of SARS-CoV-2 Spike Mutant Proteins (U.K. Variant, South Africa Variant, Brazil Variant,…) available in our webshop

human ACE2

Different human ACE-2 protein variants,  one of the most important components for Coronavirus research, available

Further Corona Proteins

Find further SARS-CoV-2 proteins: SARS-CoV-2 Proteinase 3 CL-Mpro, M protein, Envelope (E) protein and Nucleocapsid (N) protein

cGMP cell line for SARS-CoV-2 S1 (RBD)

cGMP-compliant production cell line for the SARS-CoV-2 Spike S1 (RBD) available on request

Background to the new Coronavirus SARS-CoV-2

One of the most important SARS-CoV-2 proteins for coronavirus research is the surface membrane protein Spike Glycoprotein (S). It is known to mediate the entry of the virus into human respiratory epithelial cells by interacting with the human cell surface receptor Angiotensin Converting Enzyme 2 (ACE-2).

Structure of Spike Protein

The Spike S protein of SARS-CoV-2, the receptor binding domain (RBD) of SARS-CoV-2 Spike S1 protein and the human ACE-2 protein are crucial targets in COVID-19 research for the development of therapeutic antibodies, vaccines and serological tests. In addition, other structural and non-structural SARS-CoV-2 proteins play a relevant role in COVID-19 infection like the SARS-CoV-2 Proteinase 3 CL-Mpro (controlling the activities of the coronavirus replication complex), the SARS-CoV-2 M protein (defining the shape of the virus) and the Nucleocapsid (N) protein (important for viral replication).

Our R&D is continuously working with high priority on producing further relevant recombinant SARS-CoV-2 proteins for COVID-19 research. Due to optimized production process, we also offer bulk quantities up to gram scale.

If you want to discuss your planned COVID-19 research project directly with our scientific experts or if you have any customized inquiries or suggestions for SARS-CoV-2 related protein development, please do not hesitate to contact us.

Reinhold Horlacher, PhD

Reinhold Horlacher, PhD

Managing Director & CSO

We would be happy to provide you with support on your protein research project. Let us know your questions and requests, our scientific experts will reply shortly.

Get In Contact With Our Scientific Experts

    By submitting this form, I consent to trenzyme GmbH receiving and processing my data in order to process my inquiry. My consent is voluntary and I may revoke this consent at any time without providing any reasons, e.g. by sending an email to privacy(at)trenzyme.com with effect for the future. Further notices on data processing can be found in our privacy policy.